Xiaoyan Sun

Dr. Xiaoyan Sun


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 March 2014 in Molecular Cancer
Verified
Journal Article
Open access
PDF file
YYYang Yang
Yang Yang
XCXueting Cai
Xueting Cai
JYJie Yang
Jie Yang
XSXiaoyan Sun
Xiaoyan Sun
CHChunping Hu
Chunping Hu
PCPeng Cao
Peng Cao
Nuclear factor-erythroid 2-related factor 2 (Nrf2) has emerged as a novel target for the prevention of colorectal cancer (CRC). Many chemopreventive compounds associated with Nrf2 activation are effective in preclinical systems and many on-going clinical trials are showing promising findings. In present study we evaluated the cytoprotective effect and chemopreventive properties of dietary digitoflavone.

24 April 2022 in Molecules
Verified
Journal Article
Open access
PDF file
WJWenjing Ji
Wenjing Ji
XSXiaoyan Sun
Xiaoyan Sun
YGYang Gao
Yang Gao
MLMan Lu
Man Lu
LZLingxia Zhu
Lingxia Zhu
PCPeng Cao
Peng Cao
Shikonin is the main component of root extracts from the Chinese herbal medicine Lithospermum erythrorhizon, which is commonly used for the treatment of various diseases including cancer. Previous research showed that shikonin suppressed pancreatic cancer growth; nevertheless, its molecular targets and mechanisms have not been elucidated. This study aimed to investigate the interaction and regulatory mechanisms of shikonin on its potential target p21-activated kinase 1 (PAK1). Through a labchip-based screening method, shikonin was identified as a potential bioactive PAK1 inhibitor. Molecular docking technology was used to detect the interaction sites of shikonin and PAK1 kinase. Western blot was performed to validate the mechanism. MTT and flow cytometry were practiced to investigate the effect of shikonin against pancreatic cancer cells. The results show that shikonin significantly inhibited the activity of PAK1 kinase with IC50 value of 7.252 ± 0.054 μM. Molecular docking studies showed that shikonin binds to the ATP-binding pocket of the PAK1 kinase domain. Moreover, shikonin inhibited PAK1 activation and its downstream signaling pathway proteins, while reducing proliferation and inducing apoptosis of pancreatic cancer cells. Further studies showed that the treatment of shikonin sensitized pancreatic cancer cells to chemotherapeutic drugs. These results suggest that shikonin, a potential natural inhibitor targeting PAK1 kinase, has promising potent applications in the treatment of pancreatic cancer and chemotherapy sensitization.

16 February 2022 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
DYDandan Yue
Dandan Yue
ZZZihan Zheng
Zihan Zheng
WFWeiwei Fan
Weiwei Fan
LZLizhong Zhu
Lizhong Zhu
DLDan Lin
Dan Lin
CHChunping Hu
Chunping Hu

5 April 2023 in European Journal of Pharmacology
Verified
Journal Article
Closed access
WKWeikang Kong
Weikang Kong
LZLingxia Zhu
Lingxia Zhu
TLTian Li
Tian Li
JCJiao Chen
Jiao Chen
BFBo Fan
Bo Fan
PCPeng Cao
Peng Cao

1 August 2021 in Computers in Biology and Medicine
Verified
Journal Article
Closed access
JCJiao Chen
Jiao Chen
FWFei Wu
Fei Wu
DLDan Lin
Dan Lin
WKWeikang Kong
Weikang Kong
XCXueting Cai
Xueting Cai
PCPeng Cao
Peng Cao